A Massachusetts-based synthetic biology company whose research ranges from developing pesticide alternatives for crops to a Covid-19 vaccine candidate plans to go public to advance its RNA manufacturing platform.
GreenLight Biosciences agreed to merge with Environmental Impact Acquisition Corp., a special purpose acquisition company, in a deal that values the firm — which has not yet brought a product to market — at about $1.2 billion.
Create a display name to comment
This name will appear with your comment
